# Safety and Pharmacokinetic Study of NPT 2042 Soft-gelatin Capsules Administered Orally to Healthy Adult Subjects

> **NCT05503511** · PHASE1 · COMPLETED · sponsor: **NeuroPro Therapeutics, Inc.** · enrollment: 50 (actual)

## Conditions studied

- Epilepsy
- Alzheimer Disease
- Epilepsy Intractable

## Interventions

- **DRUG:** NPT 2042 (bumetanide analog) or Matching Placebo

## Key facts

- **NCT ID:** NCT05503511
- **Lead sponsor:** NeuroPro Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-20
- **Primary completion:** 2023-03-17
- **Final completion:** 2023-03-30
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2023-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05503511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05503511, "Safety and Pharmacokinetic Study of NPT 2042 Soft-gelatin Capsules Administered Orally to Healthy Adult Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05503511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*